Analyst consensus rating
Monopar Therapeutics Analyst Rating: Strong Buy
MNPR is rated Strong Buy by 13 analysts with a $126.31 target. As of 2026-08-25.
Direct answer
Monopar Therapeutics's consensus rating is Strong Buy.
13 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $126.31.
Forecast evidence checked August 25, 2026.
Get free Monopar Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $111.36
- Average price target
- $126.31
- High price target
- $145.00
- Low price target
- $100.00
- Low target gap
- -10.2%
- Target upside
- +13.4%
- High target gap
- +30.2%
- Target range width
- 40.4%
- Consensus rating
- Strong Buy
- Analysts
- 13
- Evidence date
- August 25, 2026
- Valid through
- September 1, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Monopar Therapeutics?
Monopar Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $126.31.
How far are Monopar Therapeutics's low and high targets from the recorded price?
The low target implies -10.2%, while the high target implies +30.2%.
How many analysts are included in Monopar Therapeutics's consensus?
The verified consensus includes 13 analysts.
How is Monopar Therapeutics's target upside or downside calculated?
The average target of $126.31 is divided by the recorded price of $111.36, then one is subtracted to produce +13.4%. This does not guarantee a future return.
When was Monopar Therapeutics's analyst forecast verified?
The data was verified on 2026-08-25. The dataset is valid through 2026-09-01.